Towards evidence-based marketing: The case of childhood obesity

Contentious commodities such as tobacco, alcohol and fatty foods are bringing marketing under scrutiny from consumers and policymakers. Yet there is little agreement on whether marketing is harmful to society. Systematic review (SR), a methodology derived from clinical medicine, offers marketers a tool for providing resolution and allowing policymakers to proceed with greater confidence. This article describes how SR methods were applied for the first time to a marketing problem -- the effects of food promotion to children. The review withstood scrutiny and its findings were formally ratified by government bodies and policymakers, demonstrating that SR methods can transfer from clinical research to marketing

Sudden switch of generalized Lieb-Robinson velocity in a transverse field Ising spin chain

The Lieb-Robinson theorem states that the speed at which the correlations between two distant nodes in a spin network can be built through local interactions has an upper bound, which is called the Lieb-Robinson velocity. Our central aim is to demonstrate how to observe the Lieb-Robinson velocity in an Ising spin chain with a strong transverse field. We adopt and compare four correlation measures for characterizing different types of correlations, which include correlation function, mutual information, quantum discord, and entanglement of formation. We prove that one of correlation functions shows a special behavior depending on the parity of the spin number. All the information-theoretical correlation measures demonstrate the existence of the Lieb-Robinson velocity. In particular, we find that there is a sudden switch of the Lieb-Robinson speed with the increasing of the number of spin

Health promotion: results of focus groups with African-American men

http://dx.doi.org/10.1016/j.jomh.2010.11.00

LCLS Ultrafast Science Instruments:Conceptual Design Report

The Stanford Linear Accelerator Center (SLAC), along with Argonne National Laboratory (ANL), Lawrence Livermore National Laboratory (LLNL), and the University of California at Los Angeles (UCLA), is constructing a Free-Electron Laser (FEL) facility, which will operate in the wavelength range 1.5 nm - 0.15 nm. This FEL, the Linac Coherent Light Source (LCLS), utilizes the SLAC linac and will produce sub-picosecond pulses of short wavelength X-rays with very high peak brightness and almost complete transverse coherence. The final one-third of the SLAC linac will be used as the source of electrons for the LCLS. The high energy electrons will be transported across the SLAC Research Yard, into a tunnel which will house a long undulator. In passing through the undulator, the electrons will be bunched by the force of their own synchrotron radiation and produce an intense, monochromatic, spatially coherent beam of X-rays. By varying the electron energy, the FEL X-ray wavelength will be tunable from 1.5 nm to 0.15 nm. The LCLS will include two experimental halls as well as X-ray optics and infrastructure necessary to create a facility that can be developed for research in a variety of disciplines such as atomic physics, materials science, plasma physics and biosciences. This Conceptual Design Report, the authors believe, confirms the feasibility of designing and constructing three X-ray instruments in order to exploit the unique scientific capability of this new LCLS facility. The technical objective of the LCLS Ultrafast Science Instruments (LUSI) project is to design, build, and install at the LCLS three hard X-ray instruments that will complement the initial instrument included in the LCLS construction. As the science programs advance and new technological challenges appear, instrumentation needs to be developed and ready to conquer these new opportunities. The LCLS instrument concepts have been developed in close consultation with the scientific community through a series of workshops team meetings and focused reviews. In particular, the LUSI project instruments have been identified as meeting the most urgent needs of the scientific community based on the advice of the LCLS Scientific Advisory Committee (SAC) in response to an open call for letters of intent (LOI) from the breadth of the scientific community

CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice

Neuroinflammation and microglial activation are significant processes in Alzheimer's disease pathology. Recent genome-wide association studies have highlighted multiple immune-related genes in association with Alzheimer's disease, and experimental data have demonstrated microglial proliferation as a significant component of the neuropathology. In this study, we tested the efficacy of the selective CSF1R inhibitor JNJ-40346527 (JNJ-527) in the P301S mouse tauopathy model. We first demonstrated the anti-proliferative effects of JNJ-527 on microglia in the ME7 prion model, and its impact on the inflammatory profile, and provided potential CNS biomarkers for clinical investigation with the compound, including pharmacokinetic/pharmacodynamics and efficacy assessment by TSPO autoradiography and CSF proteomics. Then, we showed for the first time that blockade of microglial proliferation and modification of microglial phenotype leads to an attenuation of tau-induced neurodegeneration and results in functional improvement in P301S mice. Overall, this work strongly supports the potential for inhibition of CSF1R as a target for the treatment of Alzheimer's disease and other tau-mediated neurodegenerative diseases

Inflammatory biomarkers in Alzheimer's disease plasma

Introduction: Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a \u201cHoly Grail\u201d of AD research and intensively sought; however, there are no well-established plasma markers. Methods: A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed. Results: Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APO\u3b54 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71). Discussion: Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation

The mid-infrared instrument for the James Webb space telescope, II: design and build

Instrumentatio